The ASMT gene encodes acetylserotonin O-methyltransferase¹¹ acetylserotonin O-methyltransferase
Also called hydroxyindole O-methyltransferase (HIOMT), this enzyme adds a methyl group to N-acetylserotonin using SAMe as the methyl donor, the enzyme that catalyzes the final step in melatonin biosynthesis²² melatonin biosynthesis
The pathway runs: tryptophan -> serotonin -> N-acetylserotonin (via AANAT) -> melatonin (via ASMT). Without functional ASMT, your body cannot complete the conversion of serotonin-derived intermediates into melatonin -- the hormone that signals darkness to your brain, lowers core body temperature, and initiates sleep onset.

rs4446909 sits in the ASMT promoter region, 207 base pairs upstream of the transcription start site within a CCCAC box³³ CCCAC box
A regulatory DNA motif involved in controlling how much mRNA is produced from the gene. The G allele at this position reduces transcription of the ASMT gene, meaning less enzyme is produced and less melatonin is synthesized. ASMT is located in the pseudoautosomal region 1 (PAR1)⁴⁴ pseudoautosomal region 1 (PAR1)
A region at the tips of the X and Y chromosomes that recombines during meiosis just like autosomes, so it is inherited in a non-sex-linked pattern despite being on the sex chromosomes of the X and Y chromosomes, which means both men and women carry two copies and inheritance follows a standard autosomal pattern.

The Mechanism

ASMT transfers a methyl group from S-adenosylmethionine (SAMe)⁵⁵ S-adenosylmethionine (SAMe)
The universal methyl donor in human biochemistry, produced from methionine and ATP to N-acetylserotonin, producing melatonin. The enzyme is primarily expressed in the pineal gland, retina, and brain, with peak activity during darkness as part of the circadian cycle. The rs4446909 G allele disrupts promoter activity at the CCCAC box, reducing ASMT mRNA transcription. In lymphoblastoid cell lines⁶⁶ lymphoblastoid cell lines
Immortalized B cells used as a laboratory model for studying gene expression, the GG genotype is associated with dramatically lower ASMT transcript levels -- by a factor of 4 to 20 compared to the AA genotype -- and correspondingly reduced enzymatic activity.

Because ASMT catalyzes the terminal step in melatonin production, reduced enzyme levels create a bottleneck. N-acetylserotonin accumulates while melatonin output drops. This is distinct from upstream pathway disruptions (such as AANAT variants) because the substrate is available but cannot be efficiently converted to the final product.

The Evidence

The foundational study by Melke et al. (2008)⁷⁷ Melke et al. (2008)
Melke J et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry, 2008 first characterized rs4446909 as a functional promoter variant. In 278 individuals with autism spectrum disorder and 255 controls, the G allele was significantly more frequent in ASD (0.77 vs 0.70, P=0.006, OR=1.5). The study found a highly significant decrease in ASMT activity (P=2x10^-12) and melatonin levels (P=3x10^-11) in ASD individuals, with the G allele genotypes showing the lowest ASMT transcript levels (P=2x10^-8).

Etain et al. (2012)⁸⁸ Etain et al. (2012)
Etain B et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet, 2012 replicated the association in bipolar disorder, finding significant association with rs4446909 in a discovery sample (P=0.01) confirmed in 480 independent patients and 672 controls (P=0.002). The GG genotype was linked to lower ASMT mRNA and reduced enzymatic activity compared to controls (P=0.001).

A follow-up by Geoffroy et al. (2014)⁹⁹ Geoffroy et al. (2014)
Geoffroy PA et al. An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study. Genes Brain Behav, 2014 studied 53 subjects (25 bipolar patients in remission, 28 controls) and found the GG genotype was associated with longer sleep duration (P=0.03), greater activity during sleep periods (P=0.015), and greater interday circadian stability (P=0.003).

In recurrent depression, Galecki et al. (2010)¹⁰¹⁰ Galecki et al. (2010)
Galecki P et al. SNPs and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J Pineal Res, 2010 found the AA genotype was protective against depression in 181 patients versus 149 controls, while the GG genotype was associated with lower ASMT mRNA expression in both patients and controls.

Practical Implications

The clinical relevance of rs4446909 centers on melatonin production capacity. If you carry one or two G alleles, your baseline melatonin synthesis may be lower than optimal, potentially contributing to difficulty with sleep onset, lighter sleep in the first half of the night, or a tendency to feel alert later into the evening than desired.

Exogenous melatonin supplementation can compensate for reduced endogenous production. Low-dose melatonin (0.3-1 mg) taken 30-60 minutes before desired sleep time most closely mimics physiological melatonin release. Higher doses (3-5 mg) are commonly sold but may cause morning grogginess and are not necessarily more effective for sleep onset.

Supporting the upstream pathway also matters: adequate tryptophan¹¹¹¹ tryptophan
The amino acid precursor to serotonin, found in turkey, eggs, cheese, nuts, and seeds intake provides the raw material, while the methylation cycle must supply sufficient SAMe for ASMT to function. Bright light exposure in the morning and dim light in the evening help calibrate the circadian signal that drives pineal ASMT expression.

Interactions

rs4446909 is in strong linkage disequilibrium (D'=0.94) with rs5989681, another ASMT promoter variant located 97 bp upstream in a putative NF-kappaB binding site. These two SNPs tend to be inherited together and have concordant effects on ASMT expression. Most studies that find an association with rs4446909 also find it with rs5989681.

The melatonin synthesis pathway involves two enzymatic steps after serotonin: AANAT (serotonin -> N-acetylserotonin) and ASMT (N-acetylserotonin -> melatonin). Variants in AANAT could compound the effect of ASMT variants by reducing substrate availability, though this interaction is less well characterized than the ASMT promoter variants themselves.

ASMT requires SAMe as a methyl donor, creating a functional link to the methylation cycle. Variants affecting methylation capacity (such as MTHFR C677T) could theoretically compound ASMT insufficiency by limiting SAMe availability, though direct evidence for this gene-gene interaction on melatonin levels is not yet established.

Apolipoprotein A-II is the second most abundant protein in HDL particles¹¹ second most abundant protein in HDL particles
After apolipoprotein A-I; ApoA-II accounts for roughly 15-20% of total HDL protein mass, the particles traditionally associated with cardiovascular protection. Yet ApoA-II's role extends well beyond lipid transport — it appears to act as a postprandial satiety signal²² postprandial satiety signal
Released after meals, ApoA-II may communicate fat availability to appetite-regulating centers, particularly in the context of dietary fat intake. The rs5082 variant in the APOA2 promoter region is one of the most robustly replicated gene-diet interactions³³ gene-diet interactions
The modification of a genetic effect by an environmental factor — here, dietary fat intake changes whether the genotype affects body weight in the history of nutrigenetics: the same genotype that has no measurable effect in people eating a modest amount of saturated fat becomes a clinically meaningful obesity risk factor in those eating a high-saturated-fat diet.

The variant is located 265 bases upstream of the APOA2 transcription start site, placing it squarely in the promoter — the region that determines how frequently the gene is switched on. Note on allele nomenclature: the variant is traditionally named "-265T>C" using the APOA2 coding strand, which runs in the reverse direction relative to the reference genome. On the forward (plus) strand reported by 23andMe and other consumer services, the T allele corresponds to A and the C allele corresponds to G. In this profile, all genotypes use forward-strand notation: AA corresponds to the traditional TT, AG to TC, and GG to CC.

The Mechanism

In laboratory reporter assays, the C allele (G in forward-strand notation) reduces the basal transcriptional activity of the APOA2 promoter by approximately 30%⁴⁴ basal transcriptional activity of the APOA2 promoter by approximately 30%
Measured by transfecting cells with reporter constructs containing either the -265T or -265C allele compared to the T allele. Lower transcriptional activity means less ApoA-II protein in circulation. The proposed consequence is a blunted postprandial satiety signal: individuals with the GG genotype may not experience the same dietary fat-induced satiety cues as AA carriers, potentially leading to greater food intake and reduced appetite suppression after fat-rich meals.

In a landmark 2018 epigenomic and metabolomic study⁵⁵ 2018 epigenomic and metabolomic study
Using three populations with stored biosamples from the original 2009 replication study, researchers identified a specific methylation site (cg04436964) located approximately 26 kb from rs5082 that showed significantly higher methylation in GG carriers consuming high saturated fat diets across all three study populations. This methylation was negatively associated with APOA2 mRNA expression — the more methylated, the less ApoA-II produced. The researchers also found downstream metabolomic changes in GG high-SFA consumers: dysregulation of tryptophan/kynurenine and branched-chain amino acid (BCAA) metabolic pathways, implicating altered energy homeostasis and appetite regulation, not just lipid metabolism.

The Evidence

The gene-diet interaction story for rs5082 begins with the 2007 GOLDN study⁶⁶ 2007 GOLDN study
Genetics of Lipid Lowering Drugs and Diet Network; n=1,078, which first reported that CC homozygotes consumed significantly more total energy (9,371 vs 8,456 kJ/day, P=0.005), more fat, and more protein than T allele carriers, and had 1.70-fold higher obesity odds (95%CI 1.02–2.80). Crucially, the obesity association was confined to those consuming high saturated fat.

The pivotal 2009 replication study⁷⁷ 2009 replication study
Cross-sectional and prospective data from three independent U.S. populations analyzed 3,462 individuals from the Framingham Offspring Study (n=1,454), GOLDN (n=1,078), and Boston Puerto Rican Study (n=930), finding consistent results across all three. Among high saturated fat consumers (≥22g/day), GG homozygotes had 6.2% higher BMI on average (range 4.3–7.9%, P<0.05 in each cohort) and 1.84-fold higher odds of obesity (95%CI 1.38–2.47, P<0.0001). In the low-SFA group, there was no association (OR=0.81, P=0.18). This dose-threshold pattern — no effect below 22g/day, clear effect above — is the defining feature of this gene-diet interaction.

Replication extended across cultures. A 2011 study⁸⁸ 2011 study
In a Spanish Mediterranean population (n=907) and multiethnic Singapore National Health Survey (n=3,605) confirmed the interaction in Mediterranean Europeans, where GG carriers with high SFA intake had 6.8% higher BMI (P=0.018) but no difference with low SFA (P=0.316). In East Asian populations, the GG genotype is rare (<1% in Chinese, ~1.3% in Malays), limiting power but showing directionally consistent trends among Asian Indians, who have higher C allele frequency (~22%). A 2013 analysis⁹⁹ 2013 analysis
Using higher-fat dairy as a specific saturated fat source in the same U.S. populations showed that dairy-derived saturated fat specifically drives the interaction, with a dose-response relationship between higher-fat dairy servings and BMI in GG women.

The most recent evidence comes from the 2025 DIETFITS secondary analysis¹⁰¹⁰ 2025 DIETFITS secondary analysis
609 adults from the DIETFITS randomized trial of healthy low-carbohydrate vs. healthy low-fat diets, followed for 12 months. AA carriers (TT in traditional notation) lost significantly more weight on a low-carbohydrate (and thus higher-saturated-fat) diet than on a low-fat diet at 3, 6, and 12 months — suggesting that the absence of the C allele actually confers an advantage on low-carb approaches. Among GG/AG carriers, the weight-loss advantage of low-carbohydrate diets was present only at 3 months and disappeared by 12 months, consistent with the longer-term saturated fat-driven BMI accumulation in GG homozygotes. The gene-by-SFA interaction on weight loss was statistically significant at 12 months, providing randomized trial evidence — not just observational — for the dietary prescription.

Practical Actions

For GG homozygotes, the key modifiable factor is saturated fat intake. The 22g/day threshold (approximately 10% of calories in a 2,000 kcal diet) is the best-validated cutoff in the literature. Primary sources of saturated fat to reduce: fatty red meat, full-fat dairy (butter, cream, whole milk, hard cheese), tropical oils (coconut, palm), and processed foods containing partially hydrogenated fats. Replacing these with monounsaturated fat sources (olive oil, avocados, nuts) and fish preserves caloric density without activating the genotype-specific obesity pathway.

For those with the heterozygous AG genotype, the effect follows a recessive pattern — meaning a single G allele does not confer meaningful increased risk. The literature consistently treats AA and AG genotypes as equivalent in terms of obesity risk, with the elevated risk appearing specifically in GG homozygotes.

Interactions

The APOA2 rs5082 interaction with saturated fat is one of the best-documented gene-diet interactions in obesity genetics, but it does not operate in isolation. A 2023 lifestyle modification study¹¹¹¹ 2023 lifestyle modification study
Digital health intervention, n>500 found that combined classification using CETP rs9939224 and APOA2 rs5082 genotypes predicted response to lifestyle changes: the worst responders were those with CETP GG × APOA2 AG/GG (on the plus strand), highlighting that lipid-handling pathway variants compound each other. The rs9939609 variant in the FTO gene shares the same phenotypic endpoint (obesity/BMI) through a completely different mechanism (adipocyte thermogenesis rather than satiety signaling); individuals carrying risk alleles at both loci may face compounded difficulties with weight regulation and warrant more aggressive dietary intervention.

APOA2 rs5082 also interacts with the APOA5 gene (rs662799). Both genes encode apolipoproteins that influence postprandial triglyceride-rich lipoprotein metabolism, and studies have identified simultaneous effects of APOA2 and APOA5 variants on plasma lipid responses to dietary fat. The combination of APOA2 GG and APOA5 risk alleles may produce additive impairments in postprandial lipid clearance beyond the individual effects.

PPARG (Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
A nuclear receptor that controls adipocyte differentiation, lipid storage, and insulin sensitivity; the pharmacological target of thiazolidinedione insulin-sensitizing drugs such as pioglitazone and rosiglitazone) is one of the most clinically significant metabolic genes in the human genome. rs6809631 is an intronic variant located within the PPARG promoter region — a stretch of regulatory DNA that controls how much PPARG protein the cell produces. Variants here can subtly tune PPARG expression in adipose tissue and liver without altering the protein sequence itself.

The Mechanism

rs6809631 lies within an intron of PPARG on chromosome 3 (GRCh38 position 12,294,148). Intronic variants in promoter-adjacent regions can influence gene expression through several mechanisms: altering the binding affinity of transcription factor complexes at intronic enhancer elements, modifying RNA splicing²² RNA splicing
The process by which non-coding intron sequences are removed from pre-mRNA before translation — intronic variants near splice sites or branch points can subtly change which exons are included efficiency, or acting as linkage disequilibrium³³ linkage disequilibrium
The tendency of nearby variants to be co-inherited; rs6809631 may mark a functional regulatory variant elsewhere in the PPARG locus that has not been separately catalogued proxies for unidentified functional variants in the same haplotype block.

No molecular mechanism has been published for rs6809631 specifically. Its biological relevance rests on its genomic location within a gene whose regulation is deeply studied and whose activity level determines adipocyte biology at scale: PPARG transcriptionally activates hundreds of target genes controlling fat-cell differentiation, lipid uptake, and fatty acid esterification. Paradoxically, variants that modestly reduce PPARG activity — including the well-characterized Pro12Ala coding variant (rs1801282) — are associated with improved insulin sensitivity, likely because excessive PPARG-driven fat storage in visceral adipose tissue promotes ectopic lipid deposition and systemic insulin resistance. The T allele at rs6809631 may tag similar regulatory variation that reduces PPARG promoter-region activity.

The MAGIC Consortium⁴⁴ MAGIC Consortium
Dimas et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes, 2014 classified PPARG alongside IRS1, KLF14, and GCKR as one of four loci whose T2D risk operates primarily through insulin sensitivity rather than insulin secretion — establishing the functional context for all variation at this gene.

The Evidence

The primary evidence for rs6809631 derives from a case-control study nested in the Women's Health Initiative⁵⁵ case-control study nested in the Women's Health Initiative
Chan et al. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women. J Clin Endocrinol Metab, 2013 involving 1,543 T2D cases and 2,170 matched controls. Twenty-four PPARG tagSNPs were tested by multivariable logistic regression. rs6809631 was among five promoter-region variants significantly associated with reduced T2D risk (odds ratios 0.68–0.78, 95% CIs spanning 0.52–1.00, P ≤ .05). All five variants are in the same PPARG promoter haplotype block; rs9817428 from this group also independently replicated in 5,642 African American and Hispanic American women from the WHI-SHARe cohort (P = .04), strengthening the overall evidence for this haplotype region.

The evidence level for rs6809631 specifically is rated emerging: the OR is reported as a group estimate across five variants rather than per-variant, the cohort is limited to postmenopausal women, and no independent replication has been published for this exact rsid. The PPARG locus-level evidence is substantially stronger and underpins the mechanistic interpretation.

Practical Implications

Because PPARG-region variants act through insulin sensitivity — not through insulin secretion or beta-cell function — the most targeted interventions reduce insulin demand and support adipose tissue health. Omega-3 polyunsaturated fatty acids (EPA and DHA) have been shown to activate PPARγ and upregulate glucose transporters⁶⁶ activate PPARγ and upregulate glucose transporters
González-Périz et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids. FASEB J, 2009 GLUT-2 and GLUT-4, with downstream lipid mediators (resolvins, protectins) producing insulin-sensitizing effects that mirror the thiazolidinedione drug mechanism. Reducing saturated fat amplifies this benefit by reducing competition at the PPARγ ligand binding domain.

Monitoring fasting insulin and HOMA-IR detects insulin resistance before fasting glucose rises into diagnostic ranges — the earliest actionable signal for PPARG-pathway variants. For carriers with T2D or prediabetes requiring pharmacological treatment, pioglitazone directly activates PPARγ; a meta-analysis of 777 patients⁷⁷ meta-analysis of 777 patients
Jang et al. PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones. Pharmaceutics, 2023 showed PPARG Ala12 carriers achieved 0.3% greater HbA1c and ~11 mg/dL greater fasting glucose reduction on this drug class.

Interactions

rs6809631 is located in the same PPARG gene as the established Pro12Ala missense variant (rs1801282) and two other intronic tagSNPs from the same WHI study: rs9817428 and rs12636454. All three intronic variants operate in the same insulin-sensitivity pathway and may tag overlapping or independent regulatory elements within the PPARG locus. In the broader metabolic context, PPARG variants complement TCF7L2 (rs7903146), which acts through the distinct pathway of incretin signaling and insulin secretion — together these loci represent two major mechanistic axes of type 2 diabetes genetic risk.

SIRT1 (Sirtuin 1) is a NAD-dependent deacetylase¹¹ NAD-dependent deacetylase
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism with profound influence on aging, metabolism, neuroprotection, and mental health.

The sirtuin SIRT1 is expressed throughout the body, has broad biological effects and can significantly affect both cellular survival and longevity during acute and long-term injuries, which involve both oxidative stress and cell metabolism . This intronic A>G variant (rs7895833) sits in a regulatory region of the SIRT1 gene²² regulatory region of the SIRT1 gene
intronic variants can affect gene splicing, regulatory element binding, and ultimately protein expression levels and has been associated with expression levels of SIRT1 protein, particularly in aging populations.

The Mechanism

SIRT1 exerts a neuroprotective effect on various neurologic diseases through upregulation of SIRT1 which suppressed the expression levels of pro-inflammatory cytokines and increased the expression levels of superoxide dismutase 2 and catalase .

A significant increase in the SIRT1 level in older people was observed with a significant positive correlation between SIRT1 level and age, with the oldest people carrying AG genotypes for rs7895833 having the highest SIRT1 level suggesting an association between rs7895833 SNP and lifespan longevity . The G variant appears to modulate SIRT1 expression in a context-dependent manner — in some tissues and conditions increasing activity, in others potentially disrupting optimal function.

SIRT1 is a NAD+-dependent deacetylase that functions through nucleoplasmic transfer and is present in nearly all mammalian tissues, believed to deacetylate its protein substrates, resulting in neuroprotective actions, including reduced oxidative stress and inflammation, increased autophagy, increased nerve growth factors, and preserved neuronal integrity in aging or neurological disease .

The Evidence

The G allele frequency varies considerably by ancestry. A Brazilian geriatric study of 216 patients³³ A Brazilian geriatric study of 216 patients
Costa Ribeiro H et al. Polymorphism rs7895833 in the SIRT1 gene and its association with dyslipidaemia in the elderly. Rev Esp Geriatr Gerontol. 2019 found the G allele at 42% frequency and associated it with dyslipidemia. A 3-year Korean pediatric study⁴⁴ A 3-year Korean pediatric study
Lee M et al. The Gender Association of the SIRT1 rs7895833 Polymorphism with Pediatric Obesity: A 3-Year Panel Study. J Nutrigenet Nutrigenomics. 2016 of 219 children found GA+AA genotypes associated with higher BMI and obesity risk, particularly in boys who showed reduced cholesterol improvements compared to GG carriers.

rs7895833 was associated with increased odds of developing multiple sclerosis under co-dominant, overdominant, dominant, and allelic genetic models in a Lithuanian study of 250 MS patients. rs3818292 and rs7895833 were associated with an increased risk of developing exudative age-related macular degeneration, with rs7895833 associated with increased risk in women after strict Bonferroni correction .

Regarding mental health, mice with brain-specific Sirt1 knockout decreased anxiety and developed resilience to depression induced by social defeat, while mice with global Sirt1 overexpression had elevated anxiety and increased susceptibility to depression .

This behavioral phenotype was associated with a reduction in the levels of SIRT1 in the brain and in peripheral blood mononuclear cells, with peripheral blood mRNA expression of SIRT1 predicting the extent of behavioral despair only when depression-like behavior was induced by juvenile stress . Studies have linked SIRT1 to depression mechanisms⁵⁵ Studies have linked SIRT1 to depression mechanisms
Lu G et al. Role and Possible Mechanisms of Sirt1 in Depression. Oxid Med Cell Longev. 2018 through regulation of neuroinflammation, neurogenesis, and circadian control.

Practical Implications

SIRT1 is activated by NAD+ availability⁶⁶ NAD+ availability
NAD+ levels decline with age and can be supported through diet and supplementation, calorie restriction, exercise, and compounds like resveratrol (found in red wine and grapes).

Optimal SIRT1 activation is the most crucial step in the neuroprotection provided by resveratrol against cognitive impairment . For G allele carriers, whose SIRT1 regulation may be altered, supporting NAD+ metabolism through lifestyle becomes particularly relevant.

The variant's association with both metabolic conditions (obesity, dyslipidemia) and neurological/psychiatric conditions (MS, depression, AMD) reflects SIRT1's pleiotropic role in cellular stress response. The complex age-dependent and tissue-specific effects mean that G carriers may benefit from supporting SIRT1 function through multiple pathways⁷⁷ supporting SIRT1 function through multiple pathways
including NAD+ precursors, calorie restriction mimetics, and antioxidant support rather than relying on a single intervention.

Interactions

rs7895833 does not act in isolation within the SIRT1 gene.

The rs3818292-rs3758391-rs7895833 haplotype G-T-G was associated with increased odds of exudative AMD . Other SIRT1 variants including rs3818292 (intronic), rs3758391 (promoter), and rs7069102 (intron 4) have been studied in combination with rs7895833, showing that multiple regulatory variants within SIRT1 interact to modulate protein expression and disease risk. These compound effects are particularly pronounced in aging-related conditions where SIRT1's protective functions become critical.

Most people are surprised to learn that the gene controlling their allergic immune tone is partly located inside a DNA repair enzyme. The RAD50 gene¹¹ RAD50 gene
A component of the MRN (MRE11-RAD50-NBS1) complex involved in double-strand DNA break sensing and repair; its introns happen to host the Th2 cytokine locus control region, an evolutionary repurposing of non-coding DNA spans a stretch of chromosome 5q31 that also functions as the master volume control for three of the most important allergy cytokines in the human body: IL-4, IL-13, and IL-5. Nested within the final introns of RAD50 is a series of DNase I hypersensitive sites²² DNase I hypersensitive sites
Regions of chromatin that are unusually accessible to DNase I enzyme, indicating open, active regulatory DNA; they mark enhancers and locus control regions (RHS4–7) that form the Th2 locus control region (TH2-LCR). Hypersensitive site 7 (RHS7) is the most distal of these elements and is critical: deleting it in mice dramatically reduces IL-4, IL-13, and IL-5 production and collapses the long-range chromosomal architecture that allows the LCR to communicate with cytokine gene promoters over distances of tens of kilobases.

rs2240032 sits at position 132,641,435 on chromosome 5 (GRCh38), within RHS7 in intron 24 of RAD50. It is one of the most consistently replicated functional variants at this locus — not merely a statistical proxy, but a variant with documented effects on transcription factor binding, DNA methylation, and gene expression.

The Mechanism

The T allele of rs2240032 alters the binding affinity of SMAD3³³ SMAD3
A transcription factor downstream of TGF-β signalling that, paradoxically, is also recruited to Th2 regulatory elements and modulates their activity and SP1⁴⁴ SP1
Specificity protein 1, a zinc-finger transcription factor that binds GC-rich motifs and influences chromatin accessibility at regulatory elements at the RHS7 element, as shown by electrophoretic mobility shift assays (EMSA) combined with mass spectrometry proteomics. The RHS7 region itself possesses repressor activity in reporter assays, suggesting that variant-driven changes in SMAD3/SP1 occupancy fine-tune the repressive tone of the LCR rather than acting as a simple activator.

The consequence of this altered occupancy is epigenetic: the T allele is associated with changes in DNA methylation⁵⁵ DNA methylation
Addition of a methyl group to cytosine in CpG dinucleotides; hypermethylation of a gene's promoter typically silences it, hypomethylation activates it at the IL13 promoter, detectable already in cord blood — meaning the epigenetic programming is established in utero, before any environmental allergen exposure.

The Evidence

The functional characterisation was carried out by Kretschmer et al. (Allergy 2014)⁶⁶ Kretschmer et al. (Allergy 2014), who used Jurkat T-cell nuclear extracts and LC-MS/MS proteomics to demonstrate that rs2240032 drives allele-specific assembly of SMAD3, SP1, and associated protein complexes at RHS7. The same element showed repressor activity in luciferase reporter assays in both Jurkat and HeLa cells.

The clinical link was established by Schieck et al. (Allergy 2014)⁷⁷ Schieck et al. (Allergy 2014) using the PASTURE birth cohort: IL13 promoter methylation was significantly different by rs2240032 genotype in cord blood (p=0.003) and at age 4.5 years (p=0.032), demonstrating epigenetic persistence from birth into early childhood. In a larger MAGICS/ISAAC II sample of 1,145 children, the T allele was also associated with elevated total serum IgE levels (p=0.023) and altered RAD50 and IL4 gene expression.

The asthma GWAS context was established by Li et al. (2010)⁸⁸ Li et al. (2010), who identified rs2240032 in the RAD50-IL13 region at P=6.68×10⁻⁶ in 473 severe asthma cases versus 1,892 controls. Fine-mapping by Sharma et al. (Allergy 2014)⁹⁹ Sharma et al. (Allergy 2014) using 1000 Genomes Project imputation narrowed the 5q31 signal, placing rs2240032 and the nearby rs2214370 among the top associated variants at the RAD50 RHS7 locus.

Practical Actions

The T allele's effect is additive: one copy raises IL13 promoter methylation modestly; two copies compound this. Because the epigenetic imprint is set prenatally, the strategic window is early — optimising the early-life environment and monitoring for atopic sensitisation in infancy can meaningfully shift outcomes for T allele carriers. Elevated IgE is the cardinal biomarker: tracking total and specific IgE levels gives carriers an objective measure of their Th2 tone and a target for clinical intervention with allergen immunotherapy if sensitisation occurs.

Interactions

rs2240032 operates within a dense haplotype block spanning the RAD50-IL13 locus. The nearby rs2244012 (RAD50 intron 2) and the IL13 coding variant rs20541 (R130Q) have independent effects on the same Th2 axis. Fine-mapping data from Sharma et al. suggest that multi-locus haplotypes combining RHS7 variants with IL13 promoter and coding variants confer risks up to fourfold higher for elevated IgE than single variants alone. Interaction analysis combining rs2240032 with rs2244012 and rs1800925 (IL13 promoter) would be informative in clinically complex allergy cases.

The major histocompatibility complex (MHC) on chromosome 6p21 is the most gene-dense and clinically consequential region of the human genome, and rs3129934 sits within it as an intronic variant in TSBP1/C6orf10¹¹ intronic variant in TSBP1/C6orf10
Physically at 6p21.32, approximately 200 kb from the HLA-DRB1 locus and in high LD with rs3135388; annotated to TSBP1 but functions as a proxy for the entire DR15 HLA haplotype block that efficiently tags HLA-DRB5*01:01 on the DR15 susceptibility haplotype. The T allele travels with the disease-associated haplotype DRB5*01:01–DRB1*15:01–DQA1*01:02–DQB1*06:02 in near-complete linkage disequilibrium (r²=0.93) with the better-known MS tag rs3135388.

Whereas rs3135388 has been more widely studied as the DRB1*15:01 proxy, rs3129934 is physically closer to the HLA-DRB5 gene and captures an overlapping but slightly different slice of the haplotype block, making it a complementary tag — particularly useful for populations where r² with rs3135388 is lower. In European cohorts, it is considered a reliable marker of the DR15 haplotype²² reliable marker of the DR15 haplotype
Wixárika subjects from Mexico who have no reported MS were found to be uniformly homozygous CC at rs3129934, consistent with the absence of the DR15 risk haplotype with identical sensitivity and specificity for DRB5*01:01 carriage as for DRB1*15:01 carriage, because the two alleles virtually always co-occur on the same ancestral chromosome segment.

The Gene: HLA-DRB5 and the DR2a Molecule

HLA-DRB5 encodes the beta chain of the HLA-DR2a heterodimer — one of two DR molecules expressed by individuals carrying the DR15 haplotype. DR2a (DRB5*01:01 + DRA) and DR2b (DRB1*15:01 + DRA) are co-expressed on the surface of antigen-presenting cells, and both contribute to immune self-surveillance. The beta chain encoded by DRB5*01:01 has a distinct peptide-binding groove³³ distinct peptide-binding groove
The groove geometry of DR2a differs from DR2b, allowing it to bind different sets of peptide fragments — at least three myelin basic protein epitopes have been identified for DR2a versus one primary epitope for DR2b that accommodates a broader range of myelin-derived peptides than DRB1*15:01 alone.

The Mechanism

rs3129934 is a non-coding intronic variant that does not alter protein sequence; its biological significance derives entirely from tagging the full DR15 haplotype through linkage disequilibrium. The disease-relevant allele is DRB5*01:01 itself, whose protein product contributes to MS pathogenesis through two documented mechanisms.

First, DRB5*01:01 presents myelin basic protein (MBP) peptide fragments⁴⁴ myelin basic protein (MBP) peptide fragments
Particularly MBP83-99, MBP131-145, and MBP76-91 — a wider repertoire of myelin epitopes than DRB1*15:01 alone, supporting more diverse autoreactive T cell activation to CD4+ T cells on the surface of antigen-presenting cells in the brain and periphery, priming myelin-reactive T cell populations. Humanized transgenic mice expressing DRB5*01:01 alongside a patient-derived MBP-specific T cell receptor develop spontaneous experimental autoimmune encephalomyelitis⁵⁵ spontaneous experimental autoimmune encephalomyelitis
EAE is the preclinical model of MS; disease developed at a rate dependent on DR2a expression level, confirming a dose effect, establishing this allele as a direct etiologic contributor to CNS autoimmunity — not merely a bystander to DRB1*15:01.

Second, the DR15 haplotype includes a vitamin D response element (VDRE)⁶⁶ vitamin D response element (VDRE)
A regulatory DNA sequence in the DRB1*15 promoter that binds the vitamin D receptor; confirmed by Ramagopalan et al. to upregulate DRB1*15:01 expression specifically in cells carrying this allele upon vitamin D3 treatment in the promoter of the co-expressed DRB1*15:01 gene; since DRB5*01:01 and DRB1*15:01 are always inherited together on the DR15 haplotype, vitamin D insufficiency that upregulates this haplotype's expression simultaneously increases both DR2a and DR2b surface density.

Third, a T cell receptor from an MS patient has been shown to cross-recognize DRB5*01:01-restricted Epstein-Barr virus (EBV) DNA polymerase peptide⁷⁷ DRB5*01:01-restricted Epstein-Barr virus (EBV) DNA polymerase peptide
Molecular mimicry: the EBV peptide resembles MBP in structure, causing T cells trained against EBV to also attack myelin and DRB1*15:01-restricted MBP, providing a direct mechanistic bridge between EBV infection, HLA class II allele presentation, and myelin autoimmunity.

For narcolepsy, the same DR15 haplotype is the strongest known genetic risk factor. Ninety-six percent of narcolepsy type 1 patients⁸⁸ Ninety-six percent of narcolepsy type 1 patients
Narcolepsy type 1 = narcolepsy with cataplexy and low CSF hypocretin; the DRB5*01:01-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype was present in 30/31 patients (96.8%) vs 28% of population controls carry the full DR15 haplotype. T cells restricted to DRB5*01:01 and DRB1*15:01 are thought to target hypocretin-producing neurons in the lateral hypothalamus via autoimmune attack, possibly triggered by molecular mimicry with influenza or vaccine antigens in genetically susceptible individuals.

The Evidence

The pooled genome-wide scan in MS⁹⁹ pooled genome-wide scan in MS
Combined SNP chip pools from 600 MS patients and 600 controls; replication in Spanish and US independent cohorts found rs3129934 to be the single most significant HLA-region association in one of the early replicated GWASes (allele-based P=4.2×10⁻¹⁰, OR≈3 in US replication; OR=3.0 in Spanish replication), with statistical power driven by tagging the DR15 haplotype block. A multilocus analysis in three ethnically homogeneous Russian populations¹⁰¹⁰ multilocus analysis in three ethnically homogeneous Russian populations
1,049 MS cases and 816 healthy controls typed for multiple candidate SNPs across MHC and immune pathways confirmed rs3129934 T allele as the single strongest predictor (OR=2.16, 95% CI 1.85–2.74, P=2.53×10⁻¹³). In women, the TT homozygous genotype combined with a STAT3 variant conferred OR=11.87 — among the largest single-study MS risk estimates reported.

The transgenic mouse study¹¹¹¹ transgenic mouse study
Myelin-reactive CD4+ T cells bearing a patient-derived TCR restricted by DRB5*01:01 developed spontaneous EAE at 4.5% incidence in high-expressing mice, rising to 90% when disease was actively induced remains the strongest animal-model evidence that DRB5*01:01 is a causal contributor to MS pathogenesis, not simply co-inherited with the causally responsible DRB1*15:01.

Relationship to rs3135388

rs3129934 and rs3135388 are in near-complete LD (D′=0.964, R²=0.93) in Europeans and tag the same DR15 disease haplotype from slightly different physical positions — rs3135388 is near HLA-DRA while rs3129934 is in TSBP1/C6orf10, closer to HLA-DRB5. Platforms that genotype one but not the other can use either as a proxy; together they provide redundant coverage of this high-value haplotype block. The platform already holds the rs3135388 entry under HLA-DRA; this entry provides the DRB5-proximal tag and the DRB5*01:01-specific mechanistic context.

Practical Actions

For individuals carrying the T allele (the DR15 haplotype), the practical guidance centres on vitamin D optimisation, early neurological awareness, and informed monitoring for signs of narcolepsy. There is no supplement or lifestyle modification that negates the DR15 haplotype's immune configuration, but vitamin D optimisation addresses the direct transcriptional link between vitamin D levels and HLA-DR15 expression density, and represents the most evidence-supported actionable modifier available.

Interactions

rs3129934 is in near-complete LD with rs3135388 (HLA-DRA tag for DRB1*15:01). Both capture the DR15 susceptibility block; they should not be combined additively in risk calculation — they represent the same underlying haplotype. The combination with rs2300747 (CD58) is of clinical interest: CD58 regulates regulatory T cell function, and individuals carrying both the DR15 risk haplotype (reduced self-tolerance induction via DRB5*01:01 and DRB1*15:01) and reduced CD58 expression (rs2300747 AA) may face additive MS susceptibility from both antigen-presentation and immune-regulatory pathways. The rs2187668 (HLA-DQ2.5) and rs7454108 (HLA-DQ8) variants occupy the same HLA block but concern celiac disease and type 1 diabetes risk rather than MS or narcolepsy.

Glutathione S-transferase Mu 1 (GSTM1) is a Phase II detoxification enzyme¹¹ Phase II detoxification enzyme
Phase II enzymes conjugate reactive intermediates produced by Phase I (CYP450) enzymes with water-soluble molecules like glutathione, making toxins easier to excrete that plays a critical role in neutralizing environmental carcinogens, pollutants, and reactive oxygen species. It works by conjugating glutathione²² glutathione
The body's most abundant intracellular antioxidant, a tripeptide of glutamate, cysteine, and glycine to electrophilic compounds — essentially tagging dangerous molecules for safe elimination from the body.

What makes GSTM1 remarkable among genetic variants is the sheer scale of its most common polymorphism: roughly half of all people of European descent carry a complete deletion of the GSTM1 gene on both chromosomes, resulting in zero enzyme production. This is one of the most prevalent pharmacogenomic variants in the human genome.

The Mechanism

Unlike typical SNPs that change a single DNA base, the GSTM1 "null" variant involves a whole-gene deletion³³ whole-gene deletion
A ~20kb segment containing the entire GSTM1 gene is deleted through unequal homologous recombination between flanking GSTM2 and GSTM5 sequences. The rs366631 variant reported here is not the deletion itself but a tag SNP⁴⁴ tag SNP
A SNP in linkage disequilibrium with the true variant of interest, used as a proxy when the actual variant is difficult to genotype directly — a proxy that tracks the deletion status on genotyping arrays like those used by 23andMe. The AA genotype at rs366631 indicates the GSTM1 gene is absent on both chromosomes (GSTM1 null), while AG indicates one functional copy and GG indicates two functional copies.

The study that established this tag SNP relationship⁵⁵ study that established this tag SNP relationship
Girirajan S et al. Population-specific GSTM1 copy number variation. Hum Mol Genet, 2009 showed that rs366631 is technically a non-polymorphic site — the apparent genotype variation arises because the genotyping probe cross-hybridizes with a homologous sequence in the GSTM1 region. When the gene is deleted, the probe cannot bind, producing a different signal that reliably tracks deletion status.

GSTM1 is particularly important for detoxifying polycyclic aromatic hydrocarbons (PAHs)⁶⁶ polycyclic aromatic hydrocarbons (PAHs)
Carcinogenic compounds found in tobacco smoke, charred/grilled foods, diesel exhaust, and air pollution, aflatoxins⁷⁷ aflatoxins
Toxic compounds produced by certain molds that contaminate grains, nuts, and spices — potent liver carcinogens, and reactive oxygen species. Without functional GSTM1, these compounds persist longer in the body and are more likely to form DNA adducts⁸⁸ DNA adducts
Chemical bonds between carcinogens and DNA that can cause mutations and initiate cancer.

The Evidence

The health consequences of GSTM1 null status have been studied extensively, with over 1,900 published studies as cataloged in a 2022 worldwide systematic review⁹⁹ 2022 worldwide systematic review
Correia C et al. Worldwide Systematic Review of GSTM1 and GSTT1 Null Genotypes by Continent, Ethnicity, and Therapeutic Area. OMICS, 2022.

Bladder cancer has the strongest association. A pooled analysis of 17 studies¹⁰¹⁰ pooled analysis of 17 studies
Engel LS et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol, 2002 with 2,149 cases and 3,646 controls found GSTM1 null carriers had a 44% increased risk (OR 1.44, 95% CI 1.23-1.68). An updated meta-analysis¹¹¹¹ updated meta-analysis
Yu C et al. GSTM1 and GSTT1 polymorphisms are associated with increased bladder cancer risk. Oncotarget, 2016 confirmed this (OR 1.36, 95% CI 1.25-1.47) and found that individuals null for both GSTM1 and GSTT1 had an even higher risk (OR 1.84, 95% CI 1.50-2.26).

Lung cancer risk is also elevated, particularly in combination with smoking or air pollution exposure. A meta-analysis of 53 studies¹²¹² meta-analysis of 53 studies
Wang H et al. The association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population. Sci Rep, 2015 found GSTM1 null carriers had 46% higher lung cancer risk (OR 1.46, 95% CI 1.32-1.66). In never-smokers exposed to secondhand smoke for 20+ years, the risk was 2.3-fold higher for GSTM1 null individuals.

Cruciferous vegetables and sulforaphane. The relationship between GSTM1 status and cruciferous vegetable benefit is nuanced. A clinical study by Gasper et al.¹³¹³ clinical study by Gasper et al.
Gasper AV et al. Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli. Am J Clin Nutr, 2005 found that GSTM1-null individuals metabolize and excrete sulforaphane more rapidly than GSTM1-positive individuals. Paradoxically, some studies suggest GSTM1-null individuals may derive greater cancer protection from cruciferous vegetables because the isothiocyanates remain bioactive rather than being conjugated and excreted. However, this effect varies by cancer type and population, and GSTM1-null individuals still lack the enzyme's broader detoxification functions.

Practical Implications

GSTM1 null status is not a disease — it is a common genetic variation that shifts your baseline detoxification capacity. The practical response focuses on three areas: reducing toxic exposures, supporting alternative detoxification pathways, and increasing dietary protective factors.

Cruciferous vegetables (broccoli, broccoli sprouts, cauliflower, Brussels sprouts, kale, cabbage) are particularly valuable because they contain sulforaphane and other isothiocyanates¹⁴¹⁴ sulforaphane and other isothiocyanates
Compounds that induce Phase II detoxification enzymes through the Nrf2 pathway, partially compensating for the lost GSTM1 activity. Broccoli sprouts contain 20-100 times more sulforaphane precursor than mature broccoli. Supporting glutathione levels through N-acetylcysteine (NAC) provides the conjugation substrate that other GST family members (GSTP1, GSTA1) can use to partially compensate for absent GSTM1 activity.

Interactions

The most important interaction is with GSTT1 (glutathione S-transferase Theta 1), another Phase II enzyme with a common whole-gene deletion. Individuals null for both GSTM1 and GSTT1 ("double null") show significantly higher cancer risk than either deletion alone — the bladder cancer meta-analysis found OR 1.84 for double null versus OR 1.36 for GSTM1 null alone. The double null genotype reduces the overall glutathione conjugation capacity more severely because GSTM1 and GSTT1 have partially overlapping but distinct substrate specificities.

GSTM1 also interacts with NAT2 (N-acetyltransferase 2), another Phase II enzyme. Slow NAT2 acetylators who are also GSTM1 null show compounded risk for bladder cancer from aromatic amine exposure (found in tobacco smoke and certain occupational chemicals).

CYP2B6 is one of the most polymorphic drug-metabolizing enzymes in the human genome, responsible for the metabolism of approximately 8% of prescription medications including critical drugs for HIV treatment, pain management, depression, and cancer therapy. The V183G variant (c.548T>G, p.Val183Gly) is a rare missense mutation first identified in a Rwandan population study that results in near-complete loss of CYP2B6 enzymatic function. Carriers of this variant — even one copy — face significantly elevated drug plasma concentrations and toxicity risk when prescribed standard doses of CYP2B6-metabolized medications.

The Mechanism

At position 183 in the CYP2B6 protein, a valine residue is replaced by glycine. Valine is a branched-chain amino acid with a hydrophobic side chain, while glycine is the smallest amino acid with no side chain at all. Radloff et al. (2013)¹¹ Radloff et al. (2013)
Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools demonstrated through recombinant expression in COS-1 cells that this substitution causes "complete or almost complete loss-of-function" for both bupropion hydroxylation and efavirenz metabolism. Molecular docking analyses revealed that V183G produces conformational changes within the enzyme's active site that abolish substrate binding and catalysis. This is in sharp contrast to the common CYP2B6*6 (516G>T) variant, which reduces activity by roughly 70% — V183G effectively eliminates it entirely.

The Evidence

The V183G variant was discovered by Radloff et al. (2013)²² Radloff et al. (2013) in the course of sequencing the CYP2B6 gene in a Rwandan population. Of eight novel nonsynonymous variants identified, V183G was among four classified as near-complete loss-of-function (alongside p.G110V, p.I114T, and p.F213L). The variant was assigned one of five new star allele designations (CYP2B6*33–*37). The finding highlights the pharmacogenomic diversity of African populations, which are underrepresented in global databases — the G allele frequency in the ALFA database is 0.000 across 660 global samples, yet this variant has clinical significance for the populations in which it does occur.

For efavirenz, the drug most directly relevant to this variant, CPIC guidelines³³ CPIC guidelines provide Level A evidence that CYP2B6 poor metabolizer status is associated with 3–4 fold higher plasma concentrations, significantly increased CNS adverse effects (dizziness, insomnia, vivid dreams, confusion, suicidal ideation), and elevated risk of treatment discontinuation. While CPIC guidelines were primarily developed based on the common CYP2B6*6 allele, a complete loss-of-function variant like V183G would be expected to confer at least equivalent, likely greater, risk.

The clinical significance of CYP2B6 poor metabolizer status for sub-Saharan African populations is underscored by the observation from Swart et al. (2013)⁴⁴ Swart et al. (2013) that CYP2B6 genotype strongly predicts efavirenz plasma levels in South African HIV/AIDS patients, with CYP2B6*6/*6 homozygotes showing 97% specificity for supratherapeutic efavirenz concentrations. A complete loss-of-function variant compounds this pharmacokinetic vulnerability.

Practical Implications

For efavirenz-based HIV treatment — the primary clinical context where this variant matters — heterozygous carriers (GT) will experience moderately elevated drug exposure and CNS toxicity risk. For any person identified as homozygous (GG, extremely rare), standard efavirenz dosing would be contraindicated, with alternative antiretrovirals strongly preferred per CPIC guidance.

Bupropion, a prodrug requiring CYP2B6 conversion to its active metabolite hydroxybupropion, would be expected to show reduced antidepressant and smoking cessation efficacy in carriers. Methadone clearance would be markedly reduced, raising risk of QT prolongation and respiratory depression. These implications apply to all CYP2B6 poor metabolizers, regardless of the specific variant responsible.

Interactions

V183G is a standalone loss-of-function allele. It can theoretically occur in combination with other CYP2B6 reduced-function alleles (such as the common CYP2B6*6 allele defined by rs3745274), which would compound metabolic impairment further. The overall CYP2B6 metabolizer phenotype assigned in clinical practice is based on the combination of all alleles carried; a V183G allele in combination with any other reduced-function allele would result in poor or ultrarapid metabolizer classification depending on the combination. CYP2B6 activity is also inducible by rifampin and efavirenz itself; in patients on combination antiretroviral regimens, drug-drug interactions can partially modulate but not overcome the genetic deficiency.

Glucokinase¹¹ Glucokinase
GCK (hexokinase-4): the enzyme that phosphorylates glucose to glucose-6-phosphate in pancreatic beta cells and hepatocytes. Often called the "glucose sensor" of the pancreas because its kinetics require relatively high glucose concentrations to activate — allowing insulin secretion to scale with blood glucose levels (GCK) occupies a unique position in metabolic biology: it is simultaneously the glucose sensor of the pancreatic beta cell and a regulator of hepatic glucose uptake. Unlike most enzymes, glucokinase is not inhibited by its own product, which means insulin secretion scales continuously with rising blood glucose — a property that keeps fasting glucose tightly regulated. Variants at this locus therefore directly alter the glucose setpoint around which the body operates every day.

rs4607517 is an intronic GWAS variant located within the GCK gene on chromosome 7 (44,196,069 on GRCh38). It does not alter the glucokinase protein sequence directly, but it tags regulatory variation that modestly shifts glucokinase expression or function in beta cells, raising the fasting glucose concentration at which insulin secretion is triggered.

The Mechanism

GCK is expressed on the minus strand of chromosome 7, and rs4607517 sits in an intronic region. As an intronic GWAS tag SNP, it likely captures regulatory variation — altered transcription factor binding, splicing efficiency, or chromatin accessibility — that modulates how much functional glucokinase the beta cell produces. The A allele at rs4607517 (plus-strand notation) is associated with slightly lower beta-cell glucokinase activity, which shifts the glucose threshold for insulin secretion upward. This results in a predictable elevation of fasting plasma glucose: approximately 0.062 mmol/L per A allele — a modest but highly reproducible effect seen across large, independent populations.

Simultaneously, beta-cell function (measured as HOMA-B, a surrogate for insulin secretory capacity) is modestly reduced²² modestly reduced
Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 in A-allele carriers, consistent with a blunted glucose-sensing response.

The Evidence

The association between rs4607517 and fasting glucose is one of the most statistically robust findings in metabolic GWAS:

• The MAGIC consortium³³ MAGIC consortium
  Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 meta-analysis (up to 122,744 participants) reported rs4607517 associated with fasting glucose at p=7×10⁻⁹² and with reduced HOMA-B at p=2×10⁻¹⁶ — effect allele A raises fasting glucose by ~0.062 mmol/L per copy.
• An earlier confirmation in 36,610 Europeans⁴⁴ confirmation in 36,610 Europeans
  Prokopenko I et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet, 2009 reached p=1×10⁻²⁵ for the GCK locus, establishing it alongside GCKR, G6PC2, and MTNR1B as a cornerstone glycemic locus.
• The BMI-adjusted MAGIC replication across 96,496 non-diabetic individuals⁵⁵ across 96,496 non-diabetic individuals
  Manning AK et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits. Nat Genet, 2012 reached p=8×10⁻⁵⁶, confirming the additive dose-response independent of obesity status.
• Gestational diabetes associations have been replicated in multiple Asian cohorts: Ao et al. 2021⁶⁶ Ao et al. 2021
  Ao D et al. The association of the glucokinase rs4607517 polymorphism with gestational diabetes mellitus and its interaction with sweets consumption in Chinese women. Public Health Nutr, 2021 (n=1,015) reported OR 1.35 (95% CI 1.03–1.77) for GDM, amplified to OR 1.61 among women consuming sweets at least weekly. A meta-analysis of 22 studies⁷⁷ meta-analysis of 22 studies
  Mao H et al. Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. PLoS One, 2012 confirmed rs4607517 among 8 SNPs with replicated GDM association across 10,336 cases and 17,445 controls.
• Long-term trajectory data from the GLACIER study⁸⁸ GLACIER study
  Renström F et al. Genetic predisposition to long-term nondiabetic deteriorations in glucose homeostasis: ten-year follow-up of the GLACIER study. Diabetes, 2011 showed that A-allele carriers at GCK had nominally accelerated worsening of fasting glucose over a decade, contributing to 64% higher risk of progressing to impaired fasting glucose compared to non-carriers in a combined multi-locus score.

The effect size (~0.062 mmol/L per allele) places this firmly in the category of common variants with individually modest but biologically informative effects. It does not in itself confer high diabetes risk, but because it acts on the core glucose-sensing machinery, the effect is invariant across environments — unlike variants that require specific dietary or lifestyle triggers to manifest.

Practical Actions

The GCK variant's mechanism points directly at meal-timing and carbohydrate load management. Because the A allele slightly raises the glucose threshold for insulin secretion, fasting glucose is elevated even before dietary exposures compound the effect. Reducing the magnitude of glucose excursions — through lower-glycemic-index carbohydrate choices, smaller meal portions, and post-meal activity — directly reduces the burden on a slightly less sensitive beta-cell glucose sensor.

For women planning pregnancy, the GDM risk is actionable: earlier screening and attentiveness to dietary sugar intake are specifically supported by the GCK evidence. A carbohydrate intake pattern avoiding frequent simple-sugar spikes is more protective than a generic "healthy diet" recommendation in this context.

Periodic fasting glucose and HbA1c monitoring is the most direct tool for AA homozygotes to catch any upward drift before it crosses diagnostic thresholds.

Interactions

GCK rs4607517 acts on the beta-cell glucose sensor; downstream effects depend on insulin sensitivity as well. Variants reducing insulin sensitivity — such as TCF7L2 rs7903146 (incretin pathway) or PPARG rs1801282 (adipogenesis/insulin signaling) — amplify the physiological consequences of a slightly higher glucokinase setpoint. GCK-related elevated fasting glucose compounds with G6PC2 rs560887, another glycemic GWAS locus acting at the glucose-6-phosphatase step in hepatic glucose output, since the two genes regulate complementary sides of fasting glucose homeostasis.

Your cells constantly generate methylglyoxal (MG)¹¹ methylglyoxal (MG)
A reactive dicarbonyl metabolite produced as a byproduct of glycolysis — every glucose molecule your body burns generates a small amount of MG, a byproduct of burning glucose. Left unchecked, MG damages proteins and DNA by forming advanced glycation end-products (AGEs)²² advanced glycation end-products (AGEs)
Irreversible protein modifications that accumulate with age and high glucose; associated with neurological dysfunction, vascular aging, and sleep disruption. The enzyme glyoxalase 1 (GLO1) is the primary gatekeeper that converts MG into a harmless byproduct before it can react with cellular proteins.

What makes GLO1 biologically fascinating beyond detoxification is that MG is not simply a toxin — it also functions as an endogenous GABA-A receptor agonist³³ endogenous GABA-A receptor agonist
GABA-A receptors are the brain's main inhibitory chloride channels; compounds that bind and activate them produce calming, sleep-facilitating, and anxiolytic effects similar to benzodiazepines. By controlling MG levels, GLO1 effectively regulates the tone of this inhibitory neurotransmitter system. The rs4746 Glu111Ala variant changes a glutamic acid to alanine at position 111 of GLO1, reducing the enzyme's catalytic efficiency and allowing MG to accumulate to slightly higher baseline levels.

The Mechanism

The rs4746 G allele encodes alanine at position 111 of GLO1. The reference T allele encodes glutamic acid. GLO1 is located on chromosome 6 and the gene is oriented on the minus strand, so the coding sequence change is c.332A>C (Glu→Ala). Functional studies in erythrocytes and brain tissue confirm that Ala111 homozygotes show approximately a 16% reduction in GLO1 enzymatic activity⁴⁴ 16% reduction in GLO1 enzymatic activity
Itokawa et al. 2011 measured red blood cell glyoxalase activity in patients stratified by genotype; Gabriele et al. 2014 confirmed the finding in leukocytes and post-mortem brain tissue from typically developing controls.

With reduced GLO1 activity, MG is cleared more slowly, leading to two downstream consequences. First, transiently elevated MG can provide greater GABA-A receptor stimulation, as demonstrated by Distler et al. 2012⁵⁵ Distler et al. 2012
Distler MG et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest, 2012 in their landmark study showing that GLO1 overexpression in mice depleted brain MG and increased anxiety, while pharmacological GLO1 inhibition restored MG and had anxiolytic effects. Second, chronically elevated MG drives AGE accumulation⁶⁶ AGE accumulation
Advanced glycation end-products form when MG reacts irreversibly with lysine and arginine residues in proteins; they are not cleared by GLO1 and accumulate over time unless scavenged by compounds like carnosine, which impairs neuronal protein function and disrupts sleep-regulating pathways.

The Evidence

The mechanistic foundation was established by Distler et al. 2012⁷⁷ Distler et al. 2012
Distler MG et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest, 2012, showing that physiological concentrations of MG selectively activated GABA-A receptors in primary neurons. This was extended by McMurray et al. 2016⁸⁸ McMurray et al. 2016
McMurray KMJ et al. Neuronal overexpression of Glo1 or amygdalar microinjection of methylglyoxal is sufficient to regulate anxiety-like behavior in mice. Behav Brain Res, 2016, who demonstrated anatomically that direct MG injection into the basolateral amygdala produced anxiolytic effects comparable to midazolam.

At the human population level, genome-wide association studies have directly implicated the GLO1 locus in insomnia. The largest insomnia GWAS to date — Watanabe et al. 2022⁹⁹ Watanabe et al. 2022
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet, 2022 — analyzed 593,724 cases and 1,771,286 controls and found genome-wide significant signals at the GLO1 locus (p = 1×10⁻¹¹), among 554 total risk loci. GLO1 locus variants were also among 202 loci identified in the earlier Jansen et al. 2019 Nature Genetics GWAS ¹⁰¹⁰ Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet, 2019.

The sleep-AGE connection was directly measured by Li et al. 2024¹¹¹¹ Li et al. 2024
Li et al. Associations of Advanced Glycation End Products with Sleep Disorders in Chinese Adults. Nutrients, 2024, who found that elevated plasma MG-H1 (an MG-derived AGE) was significantly associated with poor sleep quality, excessive daytime sleepiness, and insomnia in 1,732 adults. This confirms that the MG → AGE axis disrupts sleep independently of its GABA-A modulatory effects.

The functional consequence of carrying Ala111 was characterized in brain tissue by Gabriele et al. 2014¹²¹² Gabriele et al. 2014
Gabriele S et al. The GLO1 C332 (Ala111) allele confers autism vulnerability: family-based genetic association and functional correlates. J Psychiatr Res, 2014, who found significantly reduced glyoxalase activity in both leukocytes and post-mortem temporocortical tissue of Ala111 allele carriers, along with a strong negative correlation between glyoxalase activity and AGE levels (τ = −0.588, P < 0.01).

Practical Implications

For GT and GG carriers, the reduced GLO1 activity creates two actionable targets. First, dietary and supplementary strategies can scavenge MG before it forms AGEs. Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide that directly reacts with and neutralizes MG — Hipkiss 2017¹³¹³ Hipkiss 2017
Hipkiss AR. On the Relationship between Energy Metabolism, Proteostasis, Aging and Parkinson's Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine. Aging Dis, 2017 reviewed evidence that carnosine's carbonyl-scavenging activity can ameliorate MG-induced pathological processes. Second, reducing dietary sources of exogenous AGEs (processed foods high in advanced glycation products) lowers the overall glycation burden on the body's detoxification systems.

Interactions

GLO1 activity is supported by vitamin B6 (pyridoxal/pyridoxamine), which functions independently as a carbonyl scavenger and complements GLO1's enzymatic role in MG detoxification. Research in the context of carbonyl stress and psychiatric conditions has found that low pyridoxal levels amplify the consequences of reduced GLO1 activity, suggesting that B6 status is a modifier of the rs4746 phenotype. GLO1 copy number variation (found in ~2% of the population) produces 2-4 fold increases in enzyme activity that dwarf the effect of the Glu111Ala SNP; individuals with GLO1 copy number gains would be expected to have lower MG and lower AGE burden even if they also carry the G allele at rs4746.